SlideShare a Scribd company logo
1 of 17
Download to read offline
What Do You Do With A Patient
Who Has High CRP and Low LDL?
Editorial Slides
VP Watch – November 27, 2002 - Volume 2, Issue 47
 More than 200 risk factors have been
suggested for atherosclerotic
cardiovascular disease.
 However, only hypercholesterolemia,
hypertension, diabetes, and smoking,
are traditionally considered as modifiable
major risk factors for CAD.
 During the last decade, atherosclerosis has
found a new face as an inflammatory disease,
with a its metabolic aspect (e.g.
hypercholesterolemia) as a background
component.
 A composite marker that reflects the combined
metabolic and inflammatory aspects of
atherosclerosis, and their interactions, is now
wanted more than ever.
 Cholesterol screening was the first
screening tests used for CAD risk
assessment and still is the major routine
clinical test.
 LDL cholesterol is the focus of current
national guidelines for the determination of
the risk of atherosclerotic cardiovascular
disease. 11
 Results of Framingham study showed
that more than 35% of CAD events occur
in people with total cholesterol of less
than 200 mg/dl. 10
 Based on this result, most of the cases
of acute MI occur in people with less
than average cholesterol levels which is
around 200-240mg/dl in the USA.
 Ridker et al showed that CRP
predicts adverse cardiovascular
events in asymptomatic healthy
populations. 4,5,14,15
 They also showed that CRP can
predict future incidence of diabetes
in apparently healthy people. 4,5,14,15
 As reported in VP Watch of this week, Ridker
and his colleagues showed that CRP is a stronger
predictor of future cardiovascular events than LDL
cholesterol. 12
 They measured CRP and LDL at base line in
(all of) 27,939 apparently healthy American
women, who were then followed for a mean of
eight years for the occurrence of myocardial
infarction, ischemic stroke, coronary
revascularization, or death from cardiovascular
causes. 12
 Seventy seven percent of all events (MI,
ischemic stroke, coronary revascularization, or
death from cardiovascular causes) occurred
among women with (normal) LDL below 160
mg/dl, and 46% occurred among those with
LDL levels below (current treatment target)
130 mg/dl. 12
 CRP and LDL levels were minimally
correlated, which shows that each biologic
marker was detecting a different group of
people at risk. 12
Results
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 3 4 5
LDL
CRP
Quintile
RelativeRisk
All Cardiovascular Events
Age-Adjusted Relative Risk of Future Cardiovascular Events, According to Base-
Line CRP and LDL Cholesterol Levels.
Adopted from: Ridker et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the
prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
 Increasing levels of CRP were
associated with increased risk of
cardiovascular events at all levels of
estimated 10-year risk based on the
Framingham risk score. 12
 Increasing CRP were associated with
increased risk of cardiovascular events
at LDL cholesterol levels below 130,
130-160, and above 160 mg/dl. 12
Results
Advantages of measuring CRP: 13
 stable over long periods
 has no diurnal variation
 can be measured inexpensively with available high-sensitivity
assays
 Not directly related to lipid metabolism
 More importantly, CRP predicts incidence
of diabetics and insulin resistance
syndrome as it does cardiovascular events,
which means it can be considered as a
cumulative risk marker of metabolic as well
as inflammatory aspects of atherosclerosis.
Conclusion:
 CRP is a stronger predictor of future
cardiovascular events than LDL.
 CRP and LDL are minimally correlated.
The combined evaluation of both CRP
and LDL is superior as a method of risk
detection to measurement of either
biologic marker alone.
 CRP now has the final verdict
to be considered as a major
risk factor/marker for
prediction of adverse
cardiovascular events.
Conclusion:
Questions:
 What do you do with a patient who
has high CRP and low LDL
(<160mg/dl)?
• What are the other useful
combinations of risk markers
(factors), like CRP and LDL in this
study, for risk assessment?
Questions:
 Do you agree that CRP, LDL, and
Coronary Calcium Score jointly can
provide a more powerful predictive
value for risk assessment?
Questions:
 What is the difference in value of CRP
in primary versus secondary
prevention?
 And which one of the following should
be used for patient follow up and
monitoring their response to treatment?
CRP, LDL, Calcium Score, or all?
1) Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126
2) Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
3) MB Pepys, GM Hirschfield:C-reactive protein and atherothrombosis. Ital Heart J 2001, 2: 196-199
4) Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–1847.
5) Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA; Ten-year mortality from cardiovascular disease in relation to
cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 Jun 14;322(24):1700-7.
6) Speidl et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J.
2002 Sep;144(3):449-55.
7) Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP; Evaluation of C-reactive protein, an inflammatory marker, and infectious serology
as risk factors for coronary artery disease and myocardial infarction.J Am Coll Cardiol. 1998 Jul;32(1):35-41.
8) Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first
myocardial infarction. Circulation. 1998; 97: 2007–2011.
9) Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially
healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study,
1984 to 1992. Circulation. 1999; 99: 237–242
10) Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-9.
11) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). JAMA 2001;285:2486-97.
12) Ridker et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl
J Med. 2002 Nov 14;347(20):1557-65.
13) Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein
measurements in healthy adults. Clin Chem 2001;47:444-50
14) Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr Measurement of C-reactive protein for the targeting of statin
therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959-65.
15) Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease
in women. N Engl J Med. 2000 Mar 23;342(12):836-43.
References

More Related Content

What's hot

What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“Arindam Pande
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!Regina Druz, MD, FACC
 
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...JAFAR ALSAID
 
The Role of Statins in Ischaemic Stroke
The Role of Statins in Ischaemic Stroke The Role of Statins in Ischaemic Stroke
The Role of Statins in Ischaemic Stroke Ade Wijaya
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofAlexander Decker
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-xAndi Wahyudi
 
HPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine LearningHPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine LearningNimai Chand Das Adhikari
 
Risc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmiesRisc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmiesCAMFiC
 
Sarnak2019
Sarnak2019Sarnak2019
Sarnak2019nazmi287
 
Management of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateManagement of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateVinh Pham Nguyen
 
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...Ancestral Health Society
 

What's hot (17)

What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!
 
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...
Proteinuria is it a risk marker or a therapeutic target for cardiovascular di...
 
The Role of Statins in Ischaemic Stroke
The Role of Statins in Ischaemic Stroke The Role of Statins in Ischaemic Stroke
The Role of Statins in Ischaemic Stroke
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
 
Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in A...
Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in A...Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in A...
Looking Beyond Lipids: A Visual Guide to Targeting Vascular Inflammation in A...
 
Osborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelinesOsborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelines
 
Impact of hba1 c
Impact of hba1 cImpact of hba1 c
Impact of hba1 c
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x
 
HPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine LearningHPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine Learning
 
Risc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmiesRisc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmies
 
Cholesterol 101
Cholesterol 101Cholesterol 101
Cholesterol 101
 
International Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & DiagnosisInternational Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & Diagnosis
 
Sarnak2019
Sarnak2019Sarnak2019
Sarnak2019
 
Dyslypedia
DyslypediaDyslypedia
Dyslypedia
 
Management of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateManagement of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of Fenofibrate
 
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...
ASH13 Scott Hall and Robb Wolf — Evaluation of the Impact of a Paleolithic Di...
 

Viewers also liked

075 immune modulation
075 immune modulation075 immune modulation
075 immune modulationSHAPE Society
 
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...SHAPE Society
 
053 histologic evidence of spio accumulation in vulnerable plaques
053 histologic evidence of spio accumulation in vulnerable plaques053 histologic evidence of spio accumulation in vulnerable plaques
053 histologic evidence of spio accumulation in vulnerable plaquesSHAPE Society
 
065 association for eradication of heart attack
065 association for eradication of heart attack065 association for eradication of heart attack
065 association for eradication of heart attackSHAPE Society
 
261 molecular genetics and micro arrays
261 molecular genetics and micro arrays261 molecular genetics and micro arrays
261 molecular genetics and micro arraysSHAPE Society
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understandingSHAPE Society
 
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...SHAPE Society
 
078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaqueSHAPE Society
 
150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac death150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac deathSHAPE Society
 
064 vulnerable thrombogenic blood
064 vulnerable thrombogenic blood064 vulnerable thrombogenic blood
064 vulnerable thrombogenic bloodSHAPE Society
 
143 plaque inflammation spio
143 plaque inflammation spio143 plaque inflammation spio
143 plaque inflammation spioSHAPE Society
 
248 carotid atherosclerotic lesion models
248 carotid atherosclerotic lesion models248 carotid atherosclerotic lesion models
248 carotid atherosclerotic lesion modelsSHAPE Society
 
212 basic molecular genetic studies in atherosclerosis
212 basic molecular genetic studies in atherosclerosis212 basic molecular genetic studies in atherosclerosis
212 basic molecular genetic studies in atherosclerosisSHAPE Society
 
244 importance of vascular remodelling
244 importance of vascular remodelling244 importance of vascular remodelling
244 importance of vascular remodellingSHAPE Society
 
502 nmr relaxation times
502 nmr relaxation times502 nmr relaxation times
502 nmr relaxation timesSHAPE Society
 

Viewers also liked (20)

075 immune modulation
075 immune modulation075 immune modulation
075 immune modulation
 
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
 
053 histologic evidence of spio accumulation in vulnerable plaques
053 histologic evidence of spio accumulation in vulnerable plaques053 histologic evidence of spio accumulation in vulnerable plaques
053 histologic evidence of spio accumulation in vulnerable plaques
 
242 lipid lowering
242 lipid lowering242 lipid lowering
242 lipid lowering
 
065 association for eradication of heart attack
065 association for eradication of heart attack065 association for eradication of heart attack
065 association for eradication of heart attack
 
261 molecular genetics and micro arrays
261 molecular genetics and micro arrays261 molecular genetics and micro arrays
261 molecular genetics and micro arrays
 
4
44
4
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
 
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
 
078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque078 infrared spectroscopy of atherosclerotic plaque
078 infrared spectroscopy of atherosclerotic plaque
 
150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac death150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac death
 
064 vulnerable thrombogenic blood
064 vulnerable thrombogenic blood064 vulnerable thrombogenic blood
064 vulnerable thrombogenic blood
 
245 mri scanner
245 mri scanner245 mri scanner
245 mri scanner
 
161 oct catheter
161 oct catheter161 oct catheter
161 oct catheter
 
143 plaque inflammation spio
143 plaque inflammation spio143 plaque inflammation spio
143 plaque inflammation spio
 
248 carotid atherosclerotic lesion models
248 carotid atherosclerotic lesion models248 carotid atherosclerotic lesion models
248 carotid atherosclerotic lesion models
 
212 basic molecular genetic studies in atherosclerosis
212 basic molecular genetic studies in atherosclerosis212 basic molecular genetic studies in atherosclerosis
212 basic molecular genetic studies in atherosclerosis
 
244 importance of vascular remodelling
244 importance of vascular remodelling244 importance of vascular remodelling
244 importance of vascular remodelling
 
208 peter libby
208 peter libby208 peter libby
208 peter libby
 
502 nmr relaxation times
502 nmr relaxation times502 nmr relaxation times
502 nmr relaxation times
 

Similar to 259 crp as a risk factor

Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke NeurologyKota
 
Lipids and cerebrovascular diseases
Lipids and cerebrovascular diseasesLipids and cerebrovascular diseases
Lipids and cerebrovascular diseasesNeurologyKota
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framinghamhospital
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trialSHAPE Society
 
Trajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd riskTrajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd riskPraveen Nagula
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofAlexander Decker
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calciumSHAPE Society
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_finalIvor Cummins
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient FELIX NUNURA
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002SHAPE Society
 
evolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptxevolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptxAdelSALLAM4
 

Similar to 259 crp as a risk factor (20)

Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
 
Lipids and cerebrovascular diseases
Lipids and cerebrovascular diseasesLipids and cerebrovascular diseases
Lipids and cerebrovascular diseases
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framingham
 
Esv2n26
Esv2n26Esv2n26
Esv2n26
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trial
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trial
 
Trajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd riskTrajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd risk
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient
 
Review of Lipid Guidelines 2011 to 2017
Review of Lipid Guidelines 2011 to 2017Review of Lipid Guidelines 2011 to 2017
Review of Lipid Guidelines 2011 to 2017
 
CVD-Report-V1.pdf
CVD-Report-V1.pdfCVD-Report-V1.pdf
CVD-Report-V1.pdf
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
Esv2n29
Esv2n29Esv2n29
Esv2n29
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
LATEST LIPID GUIDELINES satya.pptx
LATEST LIPID GUIDELINES satya.pptxLATEST LIPID GUIDELINES satya.pptx
LATEST LIPID GUIDELINES satya.pptx
 
Hypertensive Dyslipidaemics
Hypertensive DyslipidaemicsHypertensive Dyslipidaemics
Hypertensive Dyslipidaemics
 
evolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptxevolution in dyslipidemia management final.pptx
evolution in dyslipidemia management final.pptx
 
JCCR-02-00073
JCCR-02-00073JCCR-02-00073
JCCR-02-00073
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 

Recently uploaded

(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHUKanhu Charan
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 

Recently uploaded (20)

(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 

259 crp as a risk factor

  • 1. What Do You Do With A Patient Who Has High CRP and Low LDL? Editorial Slides VP Watch – November 27, 2002 - Volume 2, Issue 47
  • 2.  More than 200 risk factors have been suggested for atherosclerotic cardiovascular disease.  However, only hypercholesterolemia, hypertension, diabetes, and smoking, are traditionally considered as modifiable major risk factors for CAD.
  • 3.  During the last decade, atherosclerosis has found a new face as an inflammatory disease, with a its metabolic aspect (e.g. hypercholesterolemia) as a background component.  A composite marker that reflects the combined metabolic and inflammatory aspects of atherosclerosis, and their interactions, is now wanted more than ever.
  • 4.  Cholesterol screening was the first screening tests used for CAD risk assessment and still is the major routine clinical test.  LDL cholesterol is the focus of current national guidelines for the determination of the risk of atherosclerotic cardiovascular disease. 11
  • 5.  Results of Framingham study showed that more than 35% of CAD events occur in people with total cholesterol of less than 200 mg/dl. 10  Based on this result, most of the cases of acute MI occur in people with less than average cholesterol levels which is around 200-240mg/dl in the USA.
  • 6.  Ridker et al showed that CRP predicts adverse cardiovascular events in asymptomatic healthy populations. 4,5,14,15  They also showed that CRP can predict future incidence of diabetes in apparently healthy people. 4,5,14,15
  • 7.  As reported in VP Watch of this week, Ridker and his colleagues showed that CRP is a stronger predictor of future cardiovascular events than LDL cholesterol. 12  They measured CRP and LDL at base line in (all of) 27,939 apparently healthy American women, who were then followed for a mean of eight years for the occurrence of myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. 12
  • 8.  Seventy seven percent of all events (MI, ischemic stroke, coronary revascularization, or death from cardiovascular causes) occurred among women with (normal) LDL below 160 mg/dl, and 46% occurred among those with LDL levels below (current treatment target) 130 mg/dl. 12  CRP and LDL levels were minimally correlated, which shows that each biologic marker was detecting a different group of people at risk. 12 Results
  • 9. 0 0.5 1 1.5 2 2.5 3 3.5 4 1 2 3 4 5 LDL CRP Quintile RelativeRisk All Cardiovascular Events Age-Adjusted Relative Risk of Future Cardiovascular Events, According to Base- Line CRP and LDL Cholesterol Levels. Adopted from: Ridker et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
  • 10.  Increasing levels of CRP were associated with increased risk of cardiovascular events at all levels of estimated 10-year risk based on the Framingham risk score. 12  Increasing CRP were associated with increased risk of cardiovascular events at LDL cholesterol levels below 130, 130-160, and above 160 mg/dl. 12 Results
  • 11. Advantages of measuring CRP: 13  stable over long periods  has no diurnal variation  can be measured inexpensively with available high-sensitivity assays  Not directly related to lipid metabolism  More importantly, CRP predicts incidence of diabetics and insulin resistance syndrome as it does cardiovascular events, which means it can be considered as a cumulative risk marker of metabolic as well as inflammatory aspects of atherosclerosis.
  • 12. Conclusion:  CRP is a stronger predictor of future cardiovascular events than LDL.  CRP and LDL are minimally correlated. The combined evaluation of both CRP and LDL is superior as a method of risk detection to measurement of either biologic marker alone.
  • 13.  CRP now has the final verdict to be considered as a major risk factor/marker for prediction of adverse cardiovascular events. Conclusion:
  • 14. Questions:  What do you do with a patient who has high CRP and low LDL (<160mg/dl)? • What are the other useful combinations of risk markers (factors), like CRP and LDL in this study, for risk assessment?
  • 15. Questions:  Do you agree that CRP, LDL, and Coronary Calcium Score jointly can provide a more powerful predictive value for risk assessment?
  • 16. Questions:  What is the difference in value of CRP in primary versus secondary prevention?  And which one of the following should be used for patient follow up and monitoring their response to treatment? CRP, LDL, Calcium Score, or all?
  • 17. 1) Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126 2) Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850. 3) MB Pepys, GM Hirschfield:C-reactive protein and atherothrombosis. Ital Heart J 2001, 2: 196-199 4) Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–1847. 5) Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA; Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 Jun 14;322(24):1700-7. 6) Speidl et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J. 2002 Sep;144(3):449-55. 7) Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP; Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction.J Am Coll Cardiol. 1998 Jul;32(1):35-41. 8) Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97: 2007–2011. 9) Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99: 237–242 10) Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-9. 11) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. 12) Ridker et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65. 13) Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50 14) Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959-65. 15) Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43. References